Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience

Targeting a T cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jianjun, He, Qiuming, Subudhi, Sumit, Aparicio, Ana, Zurita-Saavedra, Amado, Lee, Da Hyun, Jimenez, Camilo, Suarez-Almazor, Maria, Sharma, Padmanee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530091/
https://www.ncbi.nlm.nih.gov/pubmed/25659583
http://dx.doi.org/10.1038/onc.2015.5
_version_ 1782384857655017472
author Gao, Jianjun
He, Qiuming
Subudhi, Sumit
Aparicio, Ana
Zurita-Saavedra, Amado
Lee, Da Hyun
Jimenez, Camilo
Suarez-Almazor, Maria
Sharma, Padmanee
author_facet Gao, Jianjun
He, Qiuming
Subudhi, Sumit
Aparicio, Ana
Zurita-Saavedra, Amado
Lee, Da Hyun
Jimenez, Camilo
Suarez-Almazor, Maria
Sharma, Padmanee
author_sort Gao, Jianjun
collection PubMed
description Targeting a T cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here, we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at M. D. Anderson Cancer Center on two different clinical trial protocols.
format Online
Article
Text
id pubmed-4530091
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-45300912016-04-01 Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience Gao, Jianjun He, Qiuming Subudhi, Sumit Aparicio, Ana Zurita-Saavedra, Amado Lee, Da Hyun Jimenez, Camilo Suarez-Almazor, Maria Sharma, Padmanee Oncogene Article Targeting a T cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here, we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at M. D. Anderson Cancer Center on two different clinical trial protocols. 2015-02-09 2015-10 /pmc/articles/PMC4530091/ /pubmed/25659583 http://dx.doi.org/10.1038/onc.2015.5 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Gao, Jianjun
He, Qiuming
Subudhi, Sumit
Aparicio, Ana
Zurita-Saavedra, Amado
Lee, Da Hyun
Jimenez, Camilo
Suarez-Almazor, Maria
Sharma, Padmanee
Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
title Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
title_full Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
title_fullStr Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
title_full_unstemmed Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
title_short Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
title_sort review of immune-related adverse events in prostate cancer patients treated with ipilimumab: md anderson experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530091/
https://www.ncbi.nlm.nih.gov/pubmed/25659583
http://dx.doi.org/10.1038/onc.2015.5
work_keys_str_mv AT gaojianjun reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT heqiuming reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT subudhisumit reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT aparicioana reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT zuritasaavedraamado reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT leedahyun reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT jimenezcamilo reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT suarezalmazormaria reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience
AT sharmapadmanee reviewofimmunerelatedadverseeventsinprostatecancerpatientstreatedwithipilimumabmdandersonexperience

Ejemplares similares